FEATURED COMPANIES
- Certara USA, Inc.
- Dassault System (Biovia)
- Evotec A.G.
- Numerate, Inc.
- Schrödinger, LLC
- Simulation Plus
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the global in-silico drug discovery market?
- What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
- How is each segment of the global in-silico drug discovery market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
- What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
- What are the key applications in the global in-silico drug discovery market? What are the major segments of these applications?
- Who are the key manufacturers of the global in-silico drug discovery market, and what are their contributions?
Global In-Silico Drug Discovery Market Forecast, 2019-2029
The in-silico drug discovery industry analysis projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029. The in-silico drug discovery market generated $2,094.5 million in revenue in 2018, in terms of value. The global in-silico drug discovery market growth has been primarily attributed to the major drivers in this market such as an emphasis on the reduction in medical errors and readmission rates, growth in the biomarker identification market and advancements in In-silico drug discovery techniques, and computational technological advancements in the field of computational biology. However, there are significant challenges that are restraining the market growth. These challenges include the high cost of methods and expensive procedures and their applications in medical treatments.
Expert Quote
“North America is the leading contributor to the in-silico drug discovery market and contributed approximately 41.65% to the global market value in 2018. This region is anticipated to grow at a significant CAGR during the forecast period 2019-2029 and continue dominating the global market in 2029. However, the Asia-Pacific region is expected to grow at the highest CAGR of 13.29% during the forecast period. In addition, the region of Europe also contributed a significant share of 28.40% to the global market in 2018.”
Scope of the Market Intelligence on the In-Silico Drug Discovery Market
The in-silico drug discovery research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the service market. In addition, the study also includes exhaustive information on the unmet needs, perception of the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the global in-silico drug discovery market.
Market Segmentation
- The global in-silico drug discovery market segmentation (on the basis of manufacturing and services) is further segmented on the basis of workflow, product, software, end-user, and region.
- The global in-silico drug discovery market segmentation (on the basis of product) is segmented into software, software as services, and consultancy as a service.
- The global in-silico drug discovery market segmentation (on the basis of the workflow) is segmented into discovery, pre-clinical tests, and clinical trials.
- The global in-silico drug discovery market segmentation (on the basis of software) is segmented into molecular modelling and de novo drug design, and pharmacophore modelling software.
- The global in-silico drug discovery market segmentation (on the basis of end-user) is segmented into contract research organizations, pharmaceutical industries, and academic and research institutes.
- The global in-silico drug discovery market segmentation (on the basis of the region) is segmented into North America, Europe, Asia-Pacific, Latin America, and rest-of-the-world.
Key Companies in the In-Silico Drug Discovery Market
The key manufacturers who have been contributing significantly to the global in-silico drug discovery market include Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group ULC, Collaborative Drug Discovery Inc., Dassault System (Biovia), Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC., Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrödinger, LLC, Selvita, Simulation Plus, and WuXi AppTec, among others.
Enterprise License customers will receive an Excel spreadsheet containing additional data.
FEATURED COMPANIES
- Certara USA, Inc.
- Dassault System (Biovia)
- Evotec A.G.
- Numerate, Inc.
- Schrödinger, LLC
- Simulation Plus
LOADING...
FEATURED COMPANIES
- Certara USA, Inc.
- Dassault System (Biovia)
- Evotec A.G.
- Numerate, Inc.
- Schrödinger, LLC
- Simulation Plus
In-silico drug discovery process is based on computational methods. The methods include management and the design of initial hit identification through virtual screening of small molecule libraries, optimization of the affinity as well as selectivity of hits, and improving the properties of the lead compounds. Computational drug designing approaches are used for the whole drug discovery process and virtual chemical library design. The costs for a pharmaceutical company to bring a drug to market from laboratories by using the drug discovery process before 2010 approaches $2 billion and 12 years of development approximately.
However, various factors make the in-silico drug discovery method as a more productive and wise approach in comparison to earlier drug discovery methods used for the drug development process. Therefore, there are alternative tools used to get answers on efficacy and safety faster, with more certainty and a lower cost. In-silico drug design can play a significant role in all stages of drug development - from the initial lead designing to final stage clinical development.
Additionally, according to data published by Supercomputing Facility for Bioinformatics and Computational Biology in 2018, by in-silico drug discovery, the process of drug development cost has reduced to approximately $880 million, and development process can be completed up to 10 to 12 years.
In-silico drug discovery method has the potential to accelerate scientific research using quick and accurate in-silico testing by using software to identify new potential drugs at a faster and cheaper rate as compared to earlier methods used for the drug discovery process.
According to the market intelligence report, titled 'Global In-Silico Drug Discovery Market - Analysis and Forecast, 2019-2029', the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029.
- Albany Molecular Research Inc.
- Certara USA, Inc.
- Charles River
- Chemical Computing Group ULC
- Collaborative Drug Discovery Inc.
- Dassault System (Biovia)
- e-therapeutics plc
- Evotec A.G.
- GVK Biosciences Private Limited
- ICAGEN, INC.
- Novo Informatics Pvt. Ltd.
- Numerate, Inc.
- PerkinElmer, Inc.
- Schrödinger, LLC
- Selvita
- Simulation Plus
- WuXi AppTec
LOADING...